October - December 2012

December 28, 2012		Takeda Well-Being Program 2012 "Giving Children in Long-term Treatment the Energy to Live"
December 25, 2012		Approval of a Once-Monthly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent in Japan
December 25, 2012		Takeda Announces Mutual Termination of Amylin / Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
December 21, 2012		Takeda Announces the Establishment of New Organization, Appointment of New Leadership and Change of Organization Name
December 21, 2012		Takeda Voluntarily Recalls a Specific Lot of its Fursultiamine HCl Preparation, ALINAMIN®-F5 Injection in Japan
December 18, 2012		Takeda to Sell Non-Colcrys URL Pharma, Inc. Generic Business to Sun Pharmaceutical
December 11, 2012		Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Hodgkin Lymphoma at ASH Annual Meeting
December 11, 2012		Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
December 10, 2012		Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study
December 10, 2012		Millennium and Takeda Report Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas
December 10, 2012		Presentations Highlight Data on VELCADE® (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma
November 26, 2012		Takeda Announces the Establishment of New Organization with Appointment of its Leadership and Change of Organization Name
November 19, 2012		Takeda Announces Appointment of New Senior Leadership
November 9, 2012		Takeda Announces Appointment of New Senior Leadership
November 6, 2012		Takeda to Acquire Envoy Therapeutics, Inc.
November 6, 2012		VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and Millennium Pipeline Agents to be Featured at American Society of Hematology Annual Meeting
October 31, 2012		Takeda and Millennium Announce European Conditional Marketing Authorisation for ADCETRIS® (Brentuximab Vedotin)
October 30, 2012		Takeda Submits a New Drug Application for Cetilistat (Development Code: ATL-962) in Japan for the Treatment of Obesity with Complications
October 25, 2012		DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
October 22, 2012		Takeda Announces Appointment of New Senior Leadership
October 5, 2012		Takeda to Acquire LigoCyte Pharmaceuticals, Inc.
October 3, 2012		TAKEDA AND ADVINUS INITIATE MULTI-YEAR DRUG DISCOVERY COLLABORATION
October 2, 2012		Takeda and Lundbeck Announce the U.S. Submission of a New Drug Application for Vortioxetine, an Investigational Drug for the Treatment of Major Depressive Disorder